Black Diamond Therapeutics (BDTX) Other Non-Current Liabilities (2018 - 2019)
Black Diamond Therapeutics' (BDTX) quarterly Other Non-Current Liabilities came in at $16000.0 in Q4 2019, down 99.6% YoY from $4.0 million in Q4 2018, and down 99.6% on a QoQ basis from $4.0 million in Q4 2018.
Black Diamond Therapeutics (BDTX) Other Non-Current Liabilities (2018 - 2019) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 2 years of Other Non-Current Liabilities data on file, last reported at $16000.0 in Q4 2019.
- Quarterly Other Non-Current Liabilities fell 99.6% year-over-year to $16000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $16000.0 (down 99.6% YoY) and the FY2019 annual result came in at $16000.0, down 99.6% from the prior year.
- Other Non-Current Liabilities retreated to $16000.0 in Q4 2019, from $4.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.0 million in Q4 2018 to a low of $16000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 16,000.00 |
| Dec 31, 2018 | 4.02 Mn |